Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy

BackgroundEsophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of ESCC is gradually increasing. Camrelizumab is one such immune checkpoint inhibitor (ICI) used for treatment. In this retrospective stud...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2022-07, Vol.13, p.953229-953229
Main Authors: Qiao, Yujin, Zhao, Cong, Li, Xiangnan, Zhao, Jia, Huang, Qi, Ding, Zheng, Zhang, Yan, Jiao, Jia, Zhang, Guoqing, Zhao, Song
Format: Article
Language:English
Subjects:
camrelizumab
efficacy
esophageal squamous cell carcinoma (ESCC)
immune checkpoint inhibitor (ICI)
Immunology
neoadjuvant chemotherapy
surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c442t-ef5a3950b3669a397c17e2b98be8467b8af3bb504d841e16927cc6ab5f113fd53
cites cdi_FETCH-LOGICAL-c442t-ef5a3950b3669a397c17e2b98be8467b8af3bb504d841e16927cc6ab5f113fd53
container_end_page 953229
container_issue
container_start_page 953229
container_title Frontiers in immunology
container_volume 13
creator Qiao, Yujin
Zhao, Cong
Li, Xiangnan
Zhao, Jia
Huang, Qi
Ding, Zheng
Zhang, Yan
Jiao, Jia
Zhang, Guoqing
Zhao, Song
description BackgroundEsophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of ESCC is gradually increasing. Camrelizumab is one such immune checkpoint inhibitor (ICI) used for treatment. In this retrospective study, we explored the efficacy, safety, and short-term perioperative prognosis of camrelizumab in combination with neoadjuvant chemotherapy for ESCC. Materials and MethodsA total of 254 Chinese patients with ESCC were enrolled in the study; 48 received camrelizumab in combination with neoadjuvant chemotherapy (C-NC group), and 206 received neoadjuvant chemotherapy (NC group). All patients underwent surgery after the completion of 2 cycles of neoadjuvant therapy. ResultsTwenty patients (20/48, 41.7%) in the C-NC group and 22 patients (22/206, 10.7%) in the NC group achieved a pathologic complete response (pCR) (p
doi_str_mv 10.3389/fimmu.2022.953229
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_47f4b5ad084a4f7eab9776fbf8b42984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_47f4b5ad084a4f7eab9776fbf8b42984</doaj_id><sourcerecordid>2697094179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-ef5a3950b3669a397c17e2b98be8467b8af3bb504d841e16927cc6ab5f113fd53</originalsourceid><addsrcrecordid>eNpVkk1v1DAQhiMEolXpD-DmI5dd4o_E8QUJrRaoVIkDcLbGznjjVRwvtlOU_nrS3QrRucwrz8xjaeatqve03nLeqY_OhzBvWc3YVjWcMfWquqZtKzarFq__01fVbc7Heg2hOOfN2-qKN4pSyfh1teyd8xbsQmDqSQaHZSHREQsh4egf5wCG-InYGIyfoPg4kT--DGTCCP1xfoCpEDtgiGXABKeFuJjI_sdudwb6kokPJ7CFrIOY42mAA9oSw_KueuNgzHj7nG-qX1_2P3ffNvffv97tPt9vrBCsbNA1wFVTG962alXSUonMqM5gJ1ppOnDcmKYWfSco0lYxaW0LpnGUctc3_Ka6u3D7CEd9Sj5AWnQEr88PMR00pOLtiFpIJ0wDfd0JEE4iGCVl64zrjGCqEyvr04V1mk3A3uJUEowvoC8rkx_0IT5oxZla77ECPjwDUvw9Yy46-GxxHGHd55w1a5WslaBSra300mpTzDmh-_cNrfWTA_TZAfrJAfriAP4XIaCmfw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2697094179</pqid></control><display><type>article</type><title>Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy</title><source>PubMed Central</source><creator>Qiao, Yujin ; Zhao, Cong ; Li, Xiangnan ; Zhao, Jia ; Huang, Qi ; Ding, Zheng ; Zhang, Yan ; Jiao, Jia ; Zhang, Guoqing ; Zhao, Song</creator><creatorcontrib>Qiao, Yujin ; Zhao, Cong ; Li, Xiangnan ; Zhao, Jia ; Huang, Qi ; Ding, Zheng ; Zhang, Yan ; Jiao, Jia ; Zhang, Guoqing ; Zhao, Song</creatorcontrib><description>BackgroundEsophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of ESCC is gradually increasing. Camrelizumab is one such immune checkpoint inhibitor (ICI) used for treatment. In this retrospective study, we explored the efficacy, safety, and short-term perioperative prognosis of camrelizumab in combination with neoadjuvant chemotherapy for ESCC. Materials and MethodsA total of 254 Chinese patients with ESCC were enrolled in the study; 48 received camrelizumab in combination with neoadjuvant chemotherapy (C-NC group), and 206 received neoadjuvant chemotherapy (NC group). All patients underwent surgery after the completion of 2 cycles of neoadjuvant therapy. ResultsTwenty patients (20/48, 41.7%) in the C-NC group and 22 patients (22/206, 10.7%) in the NC group achieved a pathologic complete response (pCR) (p&lt;0.001). Twenty-nine patients (29/48, 60.4%) in the C-NC group and 56 patients (56/206, 27.2%) in the NC group achieved major pathologic remission (MPR) (p&lt;0.001). There was a lower incidence of myelosuppression during neoadjuvant therapy in patients in the C-NC group (33/48, 68.8%) than in the NC group (174/206, 84.5%, p=0.012). The total incidence of adverse reactions during neoadjuvant therapy was also lower in the C-NC group (37/48, 77.1%) than in the NC group (189/206, 91.7%, p=0.003). Patients in the C-NC group had more lymph nodes cleared during surgery than those in the NC group (34 vs.30, p&lt;0.001). The logistic model showed that the treatment regimen, age, and presence of lymph node metastasis were influential factors for achieving a pCR in these patients (p&lt;0.001). Regarding other adverse events and surgery-related data, there were no significant differences observed between the two groups. ConclusionCamrelizumab in combination with neoadjuvant chemotherapy is an efficacious neoadjuvant regimen with an acceptable safety profile and does not increase the difficulty of surgery or the incidence of complications. A pCR is more likely to be achieved in patients treated with camrelizumab in combination with neoadjuvant chemotherapy, in younger patients, or in those without lymph node metastases.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2022.953229</identifier><identifier>PMID: 35911723</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>camrelizumab ; efficacy ; esophageal squamous cell carcinoma (ESCC) ; immune checkpoint inhibitor (ICI) ; Immunology ; neoadjuvant chemotherapy ; surgery</subject><ispartof>Frontiers in immunology, 2022-07, Vol.13, p.953229-953229</ispartof><rights>Copyright © 2022 Qiao, Zhao, Li, Zhao, Huang, Ding, Zhang, Jiao, Zhang and Zhao 2022 Qiao, Zhao, Li, Zhao, Huang, Ding, Zhang, Jiao, Zhang and Zhao</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-ef5a3950b3669a397c17e2b98be8467b8af3bb504d841e16927cc6ab5f113fd53</citedby><cites>FETCH-LOGICAL-c442t-ef5a3950b3669a397c17e2b98be8467b8af3bb504d841e16927cc6ab5f113fd53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329664/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329664/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Qiao, Yujin</creatorcontrib><creatorcontrib>Zhao, Cong</creatorcontrib><creatorcontrib>Li, Xiangnan</creatorcontrib><creatorcontrib>Zhao, Jia</creatorcontrib><creatorcontrib>Huang, Qi</creatorcontrib><creatorcontrib>Ding, Zheng</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Jiao, Jia</creatorcontrib><creatorcontrib>Zhang, Guoqing</creatorcontrib><creatorcontrib>Zhao, Song</creatorcontrib><title>Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy</title><title>Frontiers in immunology</title><description>BackgroundEsophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of ESCC is gradually increasing. Camrelizumab is one such immune checkpoint inhibitor (ICI) used for treatment. In this retrospective study, we explored the efficacy, safety, and short-term perioperative prognosis of camrelizumab in combination with neoadjuvant chemotherapy for ESCC. Materials and MethodsA total of 254 Chinese patients with ESCC were enrolled in the study; 48 received camrelizumab in combination with neoadjuvant chemotherapy (C-NC group), and 206 received neoadjuvant chemotherapy (NC group). All patients underwent surgery after the completion of 2 cycles of neoadjuvant therapy. ResultsTwenty patients (20/48, 41.7%) in the C-NC group and 22 patients (22/206, 10.7%) in the NC group achieved a pathologic complete response (pCR) (p&lt;0.001). Twenty-nine patients (29/48, 60.4%) in the C-NC group and 56 patients (56/206, 27.2%) in the NC group achieved major pathologic remission (MPR) (p&lt;0.001). There was a lower incidence of myelosuppression during neoadjuvant therapy in patients in the C-NC group (33/48, 68.8%) than in the NC group (174/206, 84.5%, p=0.012). The total incidence of adverse reactions during neoadjuvant therapy was also lower in the C-NC group (37/48, 77.1%) than in the NC group (189/206, 91.7%, p=0.003). Patients in the C-NC group had more lymph nodes cleared during surgery than those in the NC group (34 vs.30, p&lt;0.001). The logistic model showed that the treatment regimen, age, and presence of lymph node metastasis were influential factors for achieving a pCR in these patients (p&lt;0.001). Regarding other adverse events and surgery-related data, there were no significant differences observed between the two groups. ConclusionCamrelizumab in combination with neoadjuvant chemotherapy is an efficacious neoadjuvant regimen with an acceptable safety profile and does not increase the difficulty of surgery or the incidence of complications. A pCR is more likely to be achieved in patients treated with camrelizumab in combination with neoadjuvant chemotherapy, in younger patients, or in those without lymph node metastases.</description><subject>camrelizumab</subject><subject>efficacy</subject><subject>esophageal squamous cell carcinoma (ESCC)</subject><subject>immune checkpoint inhibitor (ICI)</subject><subject>Immunology</subject><subject>neoadjuvant chemotherapy</subject><subject>surgery</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkk1v1DAQhiMEolXpD-DmI5dd4o_E8QUJrRaoVIkDcLbGznjjVRwvtlOU_nrS3QrRucwrz8xjaeatqve03nLeqY_OhzBvWc3YVjWcMfWquqZtKzarFq__01fVbc7Heg2hOOfN2-qKN4pSyfh1teyd8xbsQmDqSQaHZSHREQsh4egf5wCG-InYGIyfoPg4kT--DGTCCP1xfoCpEDtgiGXABKeFuJjI_sdudwb6kokPJ7CFrIOY42mAA9oSw_KueuNgzHj7nG-qX1_2P3ffNvffv97tPt9vrBCsbNA1wFVTG962alXSUonMqM5gJ1ppOnDcmKYWfSco0lYxaW0LpnGUctc3_Ka6u3D7CEd9Sj5AWnQEr88PMR00pOLtiFpIJ0wDfd0JEE4iGCVl64zrjGCqEyvr04V1mk3A3uJUEowvoC8rkx_0IT5oxZla77ECPjwDUvw9Yy46-GxxHGHd55w1a5WslaBSra300mpTzDmh-_cNrfWTA_TZAfrJAfriAP4XIaCmfw</recordid><startdate>20220714</startdate><enddate>20220714</enddate><creator>Qiao, Yujin</creator><creator>Zhao, Cong</creator><creator>Li, Xiangnan</creator><creator>Zhao, Jia</creator><creator>Huang, Qi</creator><creator>Ding, Zheng</creator><creator>Zhang, Yan</creator><creator>Jiao, Jia</creator><creator>Zhang, Guoqing</creator><creator>Zhao, Song</creator><general>Frontiers Media S.A</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220714</creationdate><title>Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy</title><author>Qiao, Yujin ; Zhao, Cong ; Li, Xiangnan ; Zhao, Jia ; Huang, Qi ; Ding, Zheng ; Zhang, Yan ; Jiao, Jia ; Zhang, Guoqing ; Zhao, Song</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-ef5a3950b3669a397c17e2b98be8467b8af3bb504d841e16927cc6ab5f113fd53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>camrelizumab</topic><topic>efficacy</topic><topic>esophageal squamous cell carcinoma (ESCC)</topic><topic>immune checkpoint inhibitor (ICI)</topic><topic>Immunology</topic><topic>neoadjuvant chemotherapy</topic><topic>surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qiao, Yujin</creatorcontrib><creatorcontrib>Zhao, Cong</creatorcontrib><creatorcontrib>Li, Xiangnan</creatorcontrib><creatorcontrib>Zhao, Jia</creatorcontrib><creatorcontrib>Huang, Qi</creatorcontrib><creatorcontrib>Ding, Zheng</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Jiao, Jia</creatorcontrib><creatorcontrib>Zhang, Guoqing</creatorcontrib><creatorcontrib>Zhao, Song</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qiao, Yujin</au><au>Zhao, Cong</au><au>Li, Xiangnan</au><au>Zhao, Jia</au><au>Huang, Qi</au><au>Ding, Zheng</au><au>Zhang, Yan</au><au>Jiao, Jia</au><au>Zhang, Guoqing</au><au>Zhao, Song</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy</atitle><jtitle>Frontiers in immunology</jtitle><date>2022-07-14</date><risdate>2022</risdate><volume>13</volume><spage>953229</spage><epage>953229</epage><pages>953229-953229</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>BackgroundEsophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of ESCC is gradually increasing. Camrelizumab is one such immune checkpoint inhibitor (ICI) used for treatment. In this retrospective study, we explored the efficacy, safety, and short-term perioperative prognosis of camrelizumab in combination with neoadjuvant chemotherapy for ESCC. Materials and MethodsA total of 254 Chinese patients with ESCC were enrolled in the study; 48 received camrelizumab in combination with neoadjuvant chemotherapy (C-NC group), and 206 received neoadjuvant chemotherapy (NC group). All patients underwent surgery after the completion of 2 cycles of neoadjuvant therapy. ResultsTwenty patients (20/48, 41.7%) in the C-NC group and 22 patients (22/206, 10.7%) in the NC group achieved a pathologic complete response (pCR) (p&lt;0.001). Twenty-nine patients (29/48, 60.4%) in the C-NC group and 56 patients (56/206, 27.2%) in the NC group achieved major pathologic remission (MPR) (p&lt;0.001). There was a lower incidence of myelosuppression during neoadjuvant therapy in patients in the C-NC group (33/48, 68.8%) than in the NC group (174/206, 84.5%, p=0.012). The total incidence of adverse reactions during neoadjuvant therapy was also lower in the C-NC group (37/48, 77.1%) than in the NC group (189/206, 91.7%, p=0.003). Patients in the C-NC group had more lymph nodes cleared during surgery than those in the NC group (34 vs.30, p&lt;0.001). The logistic model showed that the treatment regimen, age, and presence of lymph node metastasis were influential factors for achieving a pCR in these patients (p&lt;0.001). Regarding other adverse events and surgery-related data, there were no significant differences observed between the two groups. ConclusionCamrelizumab in combination with neoadjuvant chemotherapy is an efficacious neoadjuvant regimen with an acceptable safety profile and does not increase the difficulty of surgery or the incidence of complications. A pCR is more likely to be achieved in patients treated with camrelizumab in combination with neoadjuvant chemotherapy, in younger patients, or in those without lymph node metastases.</abstract><pub>Frontiers Media S.A</pub><pmid>35911723</pmid><doi>10.3389/fimmu.2022.953229</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2022-07, Vol.13, p.953229-953229
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_47f4b5ad084a4f7eab9776fbf8b42984
source PubMed Central
subjects camrelizumab
efficacy
esophageal squamous cell carcinoma (ESCC)
immune checkpoint inhibitor (ICI)
Immunology
neoadjuvant chemotherapy
surgery
title Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T15%3A24%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20camrelizumab%20in%20combination%20with%20neoadjuvant%20chemotherapy%20for%20ESCC%20and%20its%20impact%20on%20esophagectomy&rft.jtitle=Frontiers%20in%20immunology&rft.au=Qiao,%20Yujin&rft.date=2022-07-14&rft.volume=13&rft.spage=953229&rft.epage=953229&rft.pages=953229-953229&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2022.953229&rft_dat=%3Cproquest_doaj_%3E2697094179%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c442t-ef5a3950b3669a397c17e2b98be8467b8af3bb504d841e16927cc6ab5f113fd53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2697094179&rft_id=info:pmid/35911723&rfr_iscdi=true